CD274 and neoplasm: In lung cancer, anti-PD-1 antibodies cemiplimab, nivolumab, and pembrolizumab, and anti-PD-L1 antibodies atezolizumab and durvalumab are used in the curative or metastatic settings to produce an anti-tumor immune response.